The FDA's skepticism towards Capricor's Duchenne drug could be a game-changer for rare disease treatments. It's time to question the efficacy of drugs that promise the world but underdeliver. Is the FDA's scrutiny a sign of things to come for drug companies that rely on hype over hard science?